Memantine in Pediatric Patients with Autism, Asperger Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

-
Investigator: Robert L. Hendren, DO
Sponsor: Forest Research Institute

Location(s): United States

Description

The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify eligible patients for participation in the follow-up randomized withdrawal study.